Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. - Wikidata - awgldk - TriplyDB

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

http://www.wikidata.org/entity/Q35801085

about

Melanoma: oncogenic drivers and the immune system Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations.Revisiting determinants of prognosis in cutaneous melanoma.BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.Germline determinants of clinical outcome of cutaneous melanoma.Variants in autophagy-related genes and clinical characteristics in melanoma: a population-based study Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma.Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma.Binimetinib for the treatment of NRAS-mutant melanoma.Defining Cancer Subtypes With Distinctive Etiologic Profiles: An Application to the Epidemiology of Melanoma.Genetic progression of malignant melanoma.Contemporary and potential future molecular diagnosis of melanoma.NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.Metastatic pathways in patients with cutaneous melanoma.Associations of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in melanoma.A Time-Based and Intratumoral Proteomic Assessment of a Recurrent Glioblastoma Multiforme.Playing Polo-Like Kinase in NRAS-Mutant Melanoma.Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics.Liquid biomarkers in melanoma: detection and discovery.Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen.Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.EMMPRIN/CD147 is an independent prognostic biomarker in cutaneous melanoma.A novel combination treatment against melanoma with NRAS mutation and therapy resistance.β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma.MEK inhibitors for the treatment of NRAS mutant melanoma Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

P2860

Q26775598-288DE208-E983-4D78-9325-59A608C88071 Q36026232-4907F794-7613-48A7-B100-5199DE36F49F Q36338825-F36CE81D-372E-42CE-A878-80DE948AB3BA Q37174935-1B18B77D-82D1-4254-8FDB-022AC19637DE Q37258423-17E355F6-5741-40AC-B96B-8CCD9C5C5FAE Q37430032-DEF33212-3AFC-435F-84F0-89B0C1CFFE50 Q37716437-147B8CE7-5C98-41E6-BE36-F8F887883C71 Q37738007-003B1035-14C0-44DD-90CB-00BE241068F0 Q38636033-740AA4AC-0F80-4E03-9632-8DFC0B0AD67A Q38731109-CE5009E4-ED1F-44A8-85EF-C8C5E66D6A34 Q38771870-EEF739A8-E87E-44BE-94C5-70C13F6A9108 Q38847989-C7BDAC7E-B8FA-4F55-B646-65B65E4C6B1F Q38925098-9D7D1E08-1445-401E-B2E6-F05FC29A0631 Q39024316-491B20B4-BF28-4D68-81A5-BE9746274596 Q40069925-84B34C11-A8DF-4A08-AD7D-E02F815CD3B0 Q41481825-E64915B5-3B1D-48AE-B1E2-E24E53FE4C2D Q41875182-5C19E0DE-2D01-4DF1-81CF-84E6533798EC Q47708657-4E726ACD-A462-487D-998F-37351FDB4D04 Q47726847-604DC81F-4E91-4998-9FE5-32857BB1D143 Q47978745-DE615865-ED7B-4513-8612-13280DC514EC Q48092505-C12D67A5-AA98-4225-9E2A-E14D118085C7 Q48331212-99D866EB-CBB4-42F7-B3CE-05CEB0369A4C Q49358253-99DA2AAF-878B-4206-B8C0-61B80198CC00 Q50202965-324EDBCD-C1E3-4324-9AC3-202454B8A329 Q52584711-2C514A2C-E5BD-4349-B602-544E44CC1261 Q52801913-A00D8C70-F01F-4AE0-AA56-1366A8169B9A Q53747880-DFFE6C89-5EF0-4FEF-A494-67FAB47369D4 Q56889985-075EB774-325F-45E0-B3F4-F29AE2079BA4 Q57569466-BDD042CD-3B3E-4410-B429-A313669048DA Q58739937-350D1EE4-61CC-4C19-ADD6-159D2185BF89

P2860

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.

http://www.wikidata.org/entity/Q35801085

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Association Between NRAS and B ...... Higher-Risk Primary Melanoma.

@ast

Association Between NRAS and B ...... Higher-Risk Primary Melanoma.

@en

type

label

Association Between NRAS and B ...... Higher-Risk Primary Melanoma.

@ast

Association Between NRAS and B ...... Higher-Risk Primary Melanoma.

@en

prefLabel

Association Between NRAS and B ...... Higher-Risk Primary Melanoma.

@ast

Association Between NRAS and B ...... Higher-Risk Primary Melanoma.

@en

P1433

Q35801085-E104615A-65F0-422C-B474-9EB428179CA1

P1476

Q35801085-D2A5164B-16DA-49B5-93DB-6C2BA2BC2848

P2093

Q35801085-02688DBF-AE83-4F91-9393-34E8CFE1BF05

Q35801085-067385DD-019E-4AAB-A54D-167CD7DC9B11

Q35801085-28AB2285-EEC5-455A-8A72-6F30F84A260B

Q35801085-34EE303D-A7B6-4EB8-B2E5-4C27FFC7B669

Q35801085-52D4DF0F-B1F6-42AC-8130-0268197DB2F4

Q35801085-584ECDE1-177A-4F85-B63F-2F2233649368

Q35801085-585E4F43-C6E6-4E84-9666-C8C4CC0B4B7D

Q35801085-61628DC0-A299-420A-91CF-1BB3905C5FD7

Q35801085-670590EC-1249-45A8-9BC8-C52868D6216D

Q35801085-6CF9DE14-9D57-42F6-96DB-D1CFABE8BF39

P2860

Q35801085-0323F572-8249-4936-BACE-EE4D37E53C3A

Q35801085-1645D730-3591-4A7F-A6DF-3F649E89A4F3

Q35801085-1D038681-7FCE-40BF-A8FC-0FC53D4AD007

Q35801085-1F1C8CFA-132D-464E-A26E-451565D220A9

Q35801085-2D189270-EA38-4116-9B64-A70EE8146558

Q35801085-33471666-0304-4FD3-B3D7-59DA1A20BEB5

Q35801085-366BB0F9-2180-48DE-BDC3-C41EC05FBB2D

Q35801085-39C6E65D-4646-4190-9823-3FEE6894D0F2

Q35801085-3B351F23-B1AB-4350-AC8B-A96C31449661

Q35801085-3C58E688-E148-472F-91D1-F4A936E3F854

P304

Q35801085-A364DC92-BF4C-4CAB-BD75-0C68EFE6FE44

P31

Q35801085-ACD1A4AF-962A-4D06-86A0-2BDEE63AF060

P356

Q35801085-A195A841-5BB4-4DA1-A13D-AA63AB037339

P433

Q35801085-123B593E-DCFF-4FD8-B6CD-18F77DD4412B

P478

Q35801085-1B8F7E9D-14F4-4333-8712-F5C4CCB676B5

P50

Q35801085-615462E8-2CC7-468B-84C0-DED1630C1BA6

Q35801085-61EBE58F-0D63-4F69-AA3D-7DA8BB2FED72

Q35801085-E3950B8B-6517-46B6-AF1E-8748E4D6760A

P577

Q35801085-529BA5A5-424A-4E5F-A208-926F9F4FB2D1

P5875

Q35801085-90F7EBBF-EA16-49D6-B382-BA7D6DEA47E1

P698

Q35801085-F1ED1760-E7FA-4C06-A230-DCFADEA42304

P932

Q35801085-32A125C9-5FC8-49EE-A32F-03158D008A9F

P356

JAMAONCOL.2015.0493

P1433

P1476

Association Between NRAS and B ...... Higher-Risk Primary Melanoma.

@en

P2093

Anne E Cust

http://www.w3.org/2001/XMLSchema#string

Anne Kricker

http://www.w3.org/2001/XMLSchema#string

Anne S Reiner

http://www.w3.org/2001/XMLSchema#string

Audrey Alexander

http://www.w3.org/2001/XMLSchema#string

Colin B Begg

http://www.w3.org/2001/XMLSchema#string

David W Ollila

http://www.w3.org/2001/XMLSchema#string

Eloise Parrish

http://www.w3.org/2001/XMLSchema#string

GEM Study Group

http://www.w3.org/2001/XMLSchema#string

Honglin Hao

http://www.w3.org/2001/XMLSchema#string

Jennifer I Bramson

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

Prognostic value of BRAF mutations in localized cutaneous melanoma.

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Mutations of the BRAF gene in human cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Determinants of BRAF mutations in primary melanomas

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Final version of 2009 AJCC melanoma staging and classification

P304

359-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMAONCOL.2015.0493

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Hoda Anton-Culver

Bruce Armstrong

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280029799

http://www.w3.org/2001/XMLSchema#string

P698

26146664

http://www.w3.org/2001/XMLSchema#string

P932

4486299

http://www.w3.org/2001/XMLSchema#string